Alta Partners LLC reports 200,000 shares in Sunshine Biopharma (SBFM)

Rhea-AI Filing Summary

Sunshine Biopharma Inc. ownership disclosure: Alta Partners LLC reports beneficial ownership of 200,000 shares of common stock, representing 8.6% of the class as of 07/08/2026. The filing states these shares are issuable upon exercise of outstanding warrants and lists Sole Voting and Sole Dispositive Power of 200,000 shares.

Insights

Securities Counsel

Filing documents a material passive position held via warrants.

The filing states 200,000 shares are beneficially owned "issuable upon exercise of outstanding warrants" as of 07/08/2026. The statement of sole voting and dispositive power aligns with standard beneficial ownership reporting when a filer can direct exercises.

Timing and cash‑flow treatment for any exercise are not described; subsequent filings would clarify if and when exercises occur.

Investor Relations Analyst

Position equals a meaningful single‑holder stake at 8.6%.

The disclosure quantifies ownership at 200,000 shares and lists a CUSIP 867781809, which identifies the security. The source shows ownership arises from warrants rather than currently issued shares.

Holder influence depends on whether warrants are exercised; filings about exercises or sales would change visible ownership.

Key Figures

Beneficial ownership: 200,000 shares Percent of class: 8.6% CUSIP: 867781809 +1 more

4 metrics

Beneficial ownership 200,000 shares Shares issuable upon exercise of outstanding warrants

Percent of class 8.6% Ownership percentage reported as of 07/08/2026

CUSIP 867781809 Identifier for Sunshine Biopharma common stock

Filing date / signature 07/08/2026 Date signed by Steven Cohen, Managing Member

Key Terms

beneficially owned, issuable upon exercise of outstanding warrants, Sole Dispositive Power, Schedule 13G

4 terms

beneficially owned regulatory

"Amount beneficially owned: 200,000 shares of common stock"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

issuable upon exercise of outstanding warrants financial

"representing shares of common stock issuable upon exercise of outstanding warrants"

Sole Dispositive Power regulatory

"Sole Dispositive Power 200,000.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Schedule 13G regulatory

"Item 1. (a) Name of issuer: Sunshine Biopharma Inc."

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/08/2026 - 06:06 PM Accepted by SEC EDGAR 07/08/2026 - 06:05 PM Learn about SEC filing dates

FAQ

What stake does Alta Partners LLC report in Sunshine Biopharma (SBFM)?

Alta Partners reports beneficial ownership of 200,000 shares, equal to 8.6% of common stock. The filing states those shares are issuable upon exercise of outstanding warrants, and it records sole voting and dispositive power as of 07/08/2026.

Are the 200,000 shares currently outstanding or issuable for SBFM?

The filing indicates the 200,000 shares are issuable upon exercise of outstanding warrants, not described as currently outstanding. The report ties the position explicitly to warrants rather than presently issued common stock.

Who filed the Schedule 13G for Sunshine Biopharma and when?

Alta Partners LLC filed the Schedule 13G and the document is signed by Steven Cohen, Managing Member on 07/08/2026. The filing lists Alta Partners' address in New York.

What voting and dispositive powers does Alta Partners claim for SBFM shares?

The filing states Sole Voting Power of 200,000 shares and Sole Dispositive Power of 200,000 shares. No shared voting or shared dispositive power is reported in the excerpt.

Does the Schedule 13G reveal cash proceeds or exercise timing for the warrants?

The filing does not provide cash‑flow details or timing for warrant exercises. It only states the shares are "issuable upon exercise of outstanding warrants" as of 07/08/2026; exercise mechanics are not described.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Sunshine Biopharma Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

867781809

(CUSIP Number)

07/08/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 867781809

1

Names of Reporting Persons

Alta Partners LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NEW YORK

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 200,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 200,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

200,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.6 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Sunshine Biopharma Inc.
(b)	Address of issuer's principal executive offices: 333 LAS OLAS WAY, CU4 SUITE 433, FORT LAUDERDALE, FLORIDA, 33301.
Item 2.
(a)	Name of person filing: Alta Partners LLC
(b)	Address or principal business office or, if none, residence: 1205 Franklin Avenue Garden City, New York 11530
(c)	Citizenship: New York Limited Liability Company
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP Number(s): 867781809
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 200,000 shares of common stock, representing shares of common stock issuable upon exercise of outstanding warrants.
(b)	Percent of class: 8.6%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 200,000 shares of common stock
	(ii) Shared power to vote or to direct the vote: 0 shares of common stock
	(iii) Sole power to dispose or to direct the disposition of: 200,000 shares of common stock
	(iv) Shared power to dispose or to direct the disposition of: 0 shares of common stock
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Alta Partners LLC

Signature:	/s/ Steven Cohen
Name/Title:	Steven Cohen, Managing Member
Date:	07/08/2026